CORRIGENDUM

DOI: 10.3892/mmr.2020.11813

Anticancer effect of guinacrine on diffuse large B-cell lymphoma via inhibition of MSI2-NUMB signaling pathway

SHUJUN YANG, LIXIA SHENG, KAIHONG XU, YI WANG, HUILING ZHU, PING ZHANG, QITIAN MU and GUIFANG OUYANG

Mol Med Rep 17: 522-530, 2018; DOI: 10.3892/mmr.2017.7892

Subsequently to the publication of this paper, an interested reader drew to the authors' attention that, in Fig. 1A on p. 524, the images selected to represent the Control experiments for the SU-DHL-8 and OCI-Ly01 cell lines bore some striking similarities. After having examined their original data, the authors realized that they uploaded the wrong images during the process of compiling this figure.

The corrected version of Fig. 1, showing the correct data for Fig. 1A, is shown on the next page. Note that the replacement of the erroneous data does not affect either the results or the conclusions reported in this paper, and all the authors agree to this Corrigendum. The authors are grateful to the Editor of Molecular Medicine Reports for granting them this opportunity to publish a Corrigendum, and apologize to the readership for any inconvenience caused.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.

A



Figure 1. QC inhibits the proliferation of diffuse large B-cell lymphoma cells. (A) DLBCL cell lines (SU-DHL-8 and Ly01) were incubated with QC and exhibited green fluorescence. Fluorescence intensity gradually weakened with the increase in drug concentration o. Magnification, ×100. (B) Viability of SU-DHL-8 cells and (C) OCI-Ly01 cells following treatment with QC for 48 h. The effect of QC on the growth of the (D) SU-DHL-8 and (E) OCI-Ly01 cell lines is presented. QC, quinacrine.